Immune cells from cord blood take aim at rare heart disease
NCT ID NCT07504289
First seen Apr 09, 2026 · Last updated May 12, 2026 · Updated 2 times
Summary
This study tests a new treatment using specially trained immune cells (CAR-NK cells) from donated umbilical cord blood to fight a rare, serious heart condition called light-chain cardiac amyloidosis. The cells target two proteins (BCMA and CD19) on the harmful cells. The trial includes 36 adults aged 18-75 whose disease has returned or not responded to prior therapy. The main goals are to check safety and see if the treatment helps control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIGHT CHAIN CARDIAC AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.